Home › Steatotic Liver Disease › Illinois
Steatotic Liver Disease clinical trials in Illinois
6 studies for Steatotic Liver Disease are looking for participants at sites in Illinois.
Cities in Illinois
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- University of Chicago Medical Center, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Chicago
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 21, 2026 · NCT06528314A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Chicago
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 3, 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Chicago
- 89bio Clinical Study Site, Glenview
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 3, 2026 · NCT06419374Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- RUSH University Medical Center, Chicago
Recruiting
Ages 18 to 75 · All sexes · Updated May 19, 2026 · NCT04054310Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
RecruitingPhase 2
Ages 16 to 20 · All sexes · Updated Jan 21, 2026 · NCT06355310From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.